Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.37 |
| ▸ | ADCY8 | P40145 | 2/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511969 | 0.81 | SMN1; SMN2 (0.53) | L3MBTL1SMN1; SMN2POLBHTTKDM4E | |
| SCHEMBL3513442 | 0.74 | SMN1; SMN2 (0.56) | L3MBTL1SMN1; SMN2POLBHTTKDM4E | |
| SCHEMBL4244247 | 0.74 | SMN1; SMN2 (0.77) | L3MBTL1SMN1; SMN2POLBHTTKDM4E | |
| SCHEMBL7370116 | 0.71 | SMN1; SMN2 (1.00) | L3MBTL1SMN1; SMN2POLBHTTKDM4E | |
| SCHEMBL4369997 | 0.71 | SMN1; SMN2 (0.72) | L3MBTL1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL5632532 | 0.71 | SMN1; SMN2 (0.72) | L3MBTL1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL4237733 | 0.71 | POLB (0.67) | L3MBTL1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL13744025 | 0.70 | L3MBTL1 (0.51) | L3MBTL1SMN1; SMN2POLBHTTTDP1 | |
| SCHEMBL16399159 | 0.66 | MAPT (0.49) | L3MBTL1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL16398872 | 0.65 | SMN1; SMN2 (0.48) | L3MBTL1SMN1; SMN2POLBHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145547-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM Fondazione Istituto Firc di Oncologia Molecolare (IT) | 2017-03-29 | — | — | EP | claimed |
| US-20170027896-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2017-02-02 | — | — | US | claimed |
| WO-2015155335-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2015-10-15 | — | — | WO | claimed |
| US-20100292170-A1 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | UNIVERSITY OF ROCHESTER (US) | 2010-11-18 | — | — | US | claimed |
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | PHARMACIA ITALIA S.P.A. (IT) | 2004-10-14 | — | — | US | claimed |
| EP-1406889-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | claimed |
| WO-2003006447-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | PHARMACIA ITALIA SPA (IT) | 2003-01-23 | — | — | WO | claimed |
| EP-3145547-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM Fondazione Istituto Firc di Oncologia Molecolare (IT) | 2017-03-29 | — | — | EP | disclosed |
| US-20170027896-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2017-02-02 | — | — | US | disclosed |
| WO-2015155335-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2015-10-15 | — | — | WO | disclosed |
| US-8415108-B2 | Methods for diagnosing interstitial cystitis via nuclear localization of beta-catenin | UNIVERSITY OF ROCHESTER (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100292170-A1 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | UNIVERSITY OF ROCHESTER (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009061847-A2 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | UNIVERSITY OF ROCHESTER (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | PHARMACIA ITALIA S.P.A. (IT) | 2004-10-14 | — | — | US | disclosed |
| EP-1406889-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003006447-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | PHARMACIA ITALIA SPA (IT) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | TCF4, TCF7, TCF7L2 | L3MBTL1 954/4885SMN1; SMN2 4517/4885POLB 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.